Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Steiner

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Medicinal Chemistry|September 30, 2022
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with OsimertinibUlrike Obst-Sander, Antonio Ricci, Bernd Kuhn, et al.
Journal of Medicinal Chemistry|March 18, 2025
Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo EfficacyMaude Giroud, Bernd Kuhn, Sandra Steiner, et al.
Journal of Medicinal Chemistry|January 29, 2013
Pyrrolopyrazines as selective spleen tyrosine kinase inhibitorsFernando Padilla, Niala Bhagirath, Shaoqing Chen, et al.
Journal of Medicinal Chemistry|December 11, 2012
3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo modelsMichael Soth, Johannes C Hermann, Calvin Yee, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Medicinal Chemistry|September 30, 2022
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with OsimertinibUlrike Obst-Sander, Antonio Ricci, Bernd Kuhn, et al.
Journal of Medicinal Chemistry|March 18, 2025
Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo EfficacyMaude Giroud, Bernd Kuhn, Sandra Steiner, et al.
Journal of Medicinal Chemistry|January 29, 2013
Pyrrolopyrazines as selective spleen tyrosine kinase inhibitorsFernando Padilla, Niala Bhagirath, Shaoqing Chen, et al.
Journal of Medicinal Chemistry|December 11, 2012
3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo modelsMichael Soth, Johannes C Hermann, Calvin Yee, et al.
Pageof 3